NGF (Ocular Applications Beyond NK)
What the Research Actually Shows
Human: 2 studies, 3 groups · Animal: 0 · In Vitro: 0
The molecule behind Oxervate already healed one blinding condition—now researchers are asking whether nerve growth factor eye drops can rescue dry eyes, protect glaucomatous nerves, and slow retinal degeneration
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Nerve growth factor is a protein your body already makes to keep neurons alive and healthy. One version of it—cenegermin, sold as Oxervate—is already FDA-approved for a rare corneal disease. Now researchers are testing whether the same NGF eye drops can treat dry eye disease, protect optic nerve cells in glaucoma, and slow vision loss in macular degeneration. A Phase IIa trial in 40 dry eye patients showed real improvement in both symptoms and corneal health. A Phase 1b glaucoma trial in 60 patients found encouraging trends but no clear proof yet. And a handful of case reports suggest NGF might help retinal function in AMD. The biology is solid—we know NGF works in the eye. But no Phase III trial exists for any of these newer uses, so we are still in the "promising early data" stage.
Most drugs start as an idea and spend decades trying to prove they work in humans. NGF eye drops are starting from a different position entirely—cenegermin, the recombinant human NGF formulation sold as Oxervate, is already FDA-approved for neurotrophic keratitis, a rare condition where corneal nerves die and the surface breaks down. That approval didn't just validate a product. It validated a biological principle: topical nerve growth factor can reach the tissues of the eye and trigger meaningful regeneration.
The question now is scope. If NGF eye drops can regenerate corneal nerves in neurotrophic keratitis, can they also stimulate tear production in dry eye disease? Protect retinal ganglion cells from glaucomatous damage? Slow photoreceptor degeneration in age-related macular degeneration? The early human data—a Phase IIa dry eye trial, a Phase 1b glaucoma study, scattered AMD case reports—says "maybe, but we're not there yet."
This article covers the broader NGF ocular platform: the same molecule, the same biology, applied to conditions beyond the one it's already approved for. For the cenegermin/neurotrophic keratitis story specifically, see our dedicated cenegermin article.
In This Article
Quick Facts: NGF (Ocular Applications Beyond NK) at a Glance
Type
Neurotrophic protein — 118-amino acid homodimeric growth factor
Also Known As
Nerve growth factor, rhNGF, cenegermin (when referring to the approved formulation), Oxervate
Generic Name
Nerve growth factor (recombinant human)
Brand Name
Oxervate (approved for NK only—not for dry eye, glaucoma, or AMD)
Molecular Weight
~26.5 kDa (homodimer)
Peptide Sequence
118-amino acid monomer; full-length recombinant human NGF-β
Endogenous Origin
Produced by lacrimal glands, corneal epithelium, and retinal cells; critical neurotrophic factor throughout the eye
Primary Molecular Function
Binds TrkA and p75NTR receptors → neuronal survival, axonal regeneration, epithelial trophism, tear film regulation, retinal ganglion cell neuroprotection
Active Fragment
Full-length NGF-β homodimer (not a fragment—the complete mature protein is the active form)
Related Compound Relationship
Same molecule as cenegermin (Oxervate)—this article covers investigational applications beyond the approved NK indication
Clinical Programs
Dompé: Phase IIa dry eye disease (completed), Phase 1b glaucoma neuroprotection (completed). No active Phase III programs for non-NK indications as of 2025.
Key Clinical Findings
Phase IIa dry eye (N=40): significant improvement in OSDI scores, corneal staining, and Schirmer test at 28 days. Phase 1b glaucoma (N=60): trends in visual field and RNFL thickness but no statistical significance on primary endpoint.
Route
Topical ophthalmic drops (20 mcg/mL concentration in clinical studies)
WADA Status
Not on Prohibited Lists
FDA Status
Not approved for dry eye, glaucoma, or AMD. Approved only for neurotrophic keratitis (as cenegermin/Oxervate, 2018).
Biggest Evidence Gap
No Phase III trial for any non-NK ocular indication. All existing data is Phase IIa or earlier.
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Reasonable Bet
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is NGF (Ocular Applications Beyond NK)?
Pronunciation: en-jee-eff OCK-yoo-lar
Nerve growth factor was the first neurotrophin ever discovered—Rita Levi-Montalcini identified it in the 1950s, work that earned her the Nobel Prize in 1986. For decades, NGF was studied primarily as a brain and peripheral nerve molecule. The eye was a secondary consideration. But the eye turned out to be one of NGF's most important territories.
NGF is produced by the lacrimal glands, corneal epithelium, conjunctival cells, and retinal neurons. It acts through two receptors—TrkA (high-affinity, pro-survival) and p75NTR (low-affinity, context-dependent)—to maintain the health of corneal nerves, support tear film homeostasis, protect retinal ganglion cells from apoptosis, and sustain photoreceptor function. Remove NGF signaling from the eye, and things fall apart: corneal nerves degenerate, the tear film breaks down, retinal neurons die.
Cenegermin—the recombinant human NGF formulation approved as Oxervate—proved this biology was therapeutically actionable. In neurotrophic keratitis, where corneal nerves have been destroyed by herpes, diabetes, or surgery, topical NGF eye drops regenerated the nerve plexus and healed persistent epithelial defects that had resisted every other treatment. The approval was a landmark: the first topical biologic for a corneal disease.
But neurotrophic keratitis affects roughly 5 in 10,000 people. Dry eye disease affects 344 million. Glaucoma affects 80 million. Age-related macular degeneration affects 200 million. If NGF eye drops can address even a fraction of those conditions, the clinical impact would be transformative.
PLAIN ENGLISH
NGF is a protein your body uses to keep nerve cells alive and healthy. The eye makes its own NGF and depends on it for everything from tear production to retinal cell survival. A version of NGF eye drops (Oxervate) is already approved for a rare corneal nerve disease. Researchers are now asking whether the same drops can help with much more common eye conditions—dry eye, glaucoma, and macular degeneration.
Origins and Discovery
The story of NGF in the eye begins with Levi-Montalcini's foundational discovery, but the ocular applications emerged decades later—primarily through the work of Italian researchers at the University of Rome and Dompé farmaceutici.
The critical insight came from observational studies showing that NGF levels are altered in ocular surface diseases. Patients with dry eye disease have lower NGF concentrations in their tears. Glaucoma patients show disrupted NGF signaling in the retina. These weren't just correlations—when researchers administered exogenous NGF to animal models of these conditions, the results were protective: reduced corneal damage, improved tear production, enhanced retinal ganglion cell survival.
Dompé took these academic findings and built a clinical development program. The neurotrophic keratitis program came first, leading to cenegermin's approval. But the dry eye and glaucoma programs were always part of the broader vision—NGF as a platform molecule for multiple ocular conditions, not a single-indication drug.
The AMD connection came from a different direction entirely. Case reports from Lambiase and colleagues showed that NGF eye drops improved visual acuity and electrofunctional measures in AMD patients—an unexpected finding that suggested NGF's neuroprotective effects might extend all the way to the photoreceptors and retinal pigment epithelium.
PLAIN ENGLISH
Italian researchers noticed that people with dry eyes, glaucoma, and macular degeneration had abnormal levels of NGF in their eyes. When they gave NGF eye drops to animals with similar conditions, the drops helped. The company behind Oxervate (Dompé) has been developing NGF as a treatment platform for multiple eye diseases, not just the rare one it's approved for.
Mechanism of Action
⚠ CRITICAL SAFETY WARNING
Some routes of administration described in the research literature — including injections into or near eyes, joints, or the spinal column — are specialized medical procedures. They require sterile clinical environments, imaging guidance, and trained physicians. Attempting these injections outside a medical setting can cause permanent injury, blindness, joint destruction, paralysis, or death.
Do not attempt specialized injections based on information in this article. This content describes what researchers did in controlled clinical settings. It is not a protocol you can replicate at home.
NGF exerts its ocular effects through two receptor systems that converge on cell survival, regeneration, and functional maintenance.
TrkA Signaling—The Survival Pathway
The high-affinity TrkA receptor mediates most of NGF's neuroprotective and trophic effects. When NGF binds TrkA on corneal nerve endings, it activates the PI3K/Akt and MAPK/ERK cascades—the same pro-survival signaling pathways that keep neurons alive throughout the nervous system. In the cornea, this means nerve fiber regeneration, enhanced epithelial proliferation, and restored sensation. In the retina, TrkA activation in ganglion cells promotes survival against the chronic pressure-induced apoptosis that characterizes glaucoma.
p75NTR—Context-Dependent Modulation
The p75NTR receptor adds complexity. Depending on cellular context and co-receptor expression, p75NTR can either amplify TrkA survival signals or trigger apoptotic pathways. In the healthy eye, the balance favors survival. In pathological states—particularly advanced glaucoma where pro-NGF (the unprocessed precursor) accumulates—the balance may shift toward cell death. This dual receptor biology is one reason NGF's therapeutic window requires careful calibration.
Dry Eye—Restoring the Neurotrophic Loop
In dry eye disease, the mechanism is fundamentally about restoring a broken feedback loop. Healthy corneal nerves signal the lacrimal glands to produce tears. Dry eye disrupts this neurotrophic loop—damaged nerves send weaker signals, tear production falls, the ocular surface dries further, and the drying damages more nerves. NGF eye drops aim to break this cycle by regenerating corneal nerve density, which restores lacrimal gland signaling and tear production. The Phase IIa data showing improved Schirmer test scores (a measure of tear volume) supports this mechanism.
Glaucoma—Neuroprotection at the Optic Nerve Head
Glaucoma destroys retinal ganglion cells (RGCs) through a combination of elevated intraocular pressure, vascular insufficiency, and excitotoxicity. Current glaucoma treatments lower pressure but do nothing to protect the neurons themselves. NGF offers a fundamentally different approach: direct neuroprotection. In animal models, topical NGF reaches the retina (likely via corneal nerve retrograde transport and transconjunctival absorption) and activates TrkA on RGCs, promoting survival even under continued pressure stress.
AMD—Photoreceptor and RPE Support
The AMD mechanism is the least established but potentially the most significant. NGF receptors are expressed on photoreceptors and retinal pigment epithelium cells. Case reports suggest that topical NGF can improve electrophysiological measures of retinal function in AMD patients—implying that NGF reaches the posterior segment and exerts neurotrophic effects on outer retinal cells. Whether this occurs through direct penetration, retrograde neural transport, or secondary signaling cascades remains unclear.
PLAIN ENGLISH
NGF works by binding to receptors on nerve cells and telling them to stay alive and keep growing. In the eye, this has three potential applications: (1) regenerating the corneal nerves that control tear production, breaking the vicious cycle of dry eye; (2) protecting the retinal nerve cells that glaucoma slowly kills; and (3) supporting the light-sensing cells in the back of the eye that degenerate in macular degeneration. The dry eye mechanism is the most straightforward. The glaucoma mechanism is biologically sound but clinically unproven at Phase III scale. The AMD mechanism is the most speculative.
Key Research Areas and Studies
Dry Eye Disease
The centerpiece is Sacchetti et al.'s Phase IIa open-label study (2019, PMID 30944103). Forty patients with moderate-to-severe dry eye disease received rhNGF eye drops (20 mcg/mL or 4 mcg/mL) for 28 days. Both concentrations produced significant improvements in the Ocular Surface Disease Index (OSDI), corneal fluorescein staining, and Schirmer test scores. The magnitude of improvement was clinically meaningful, not just statistically significant—patients reported fewer symptoms and showed objective signs of corneal healing and increased tear production.
The limitation is design: open-label, no placebo arm, 28-day duration. The improvements could reflect natural history, placebo effect, or the known benefits of any lubricating eye drop. A controlled Phase IIb or Phase III trial is needed to confirm the signal.
Glaucoma Neuroprotection
The Phase 1b randomized controlled trial (PMID 34780798) enrolled 60 glaucoma patients already on standard pressure-lowering therapy. Participants received short-course topical rhNGF or placebo. The primary endpoint—neuroenhancement measured by visual field sensitivity and retinal nerve fiber layer (RNFL) thickness—did not achieve statistical significance. However, trends in both measures favored the NGF group, and the safety profile was acceptable.
This result is neither a failure nor a success. The study was powered for safety and dose-finding, not efficacy. Glaucoma neuroprotection trials are notoriously difficult—the disease progresses slowly, endpoints require large samples and long follow-up, and any neuroprotective signal sits on top of the substantial effect of pressure reduction. A definitive answer will require a much larger, longer trial.
Age-Related Macular Degeneration
Lambiase et al. (2009, PMID 20061666) reported that NGF eye drops improved visual acuity and electrophysiological measures in a small number of AMD patients. This is case-report-level evidence—provocative but far from definitive. The finding that topical NGF can affect posterior segment function is itself noteworthy, as most topical drugs cannot reach the retina in therapeutic concentrations. No follow-up study has been published, and no clinical trial for NGF in AMD is registered.
PLAIN ENGLISH
Three lines of research are exploring NGF beyond its approved use. The dry eye study (40 patients, 28 days) showed real improvements in symptoms and tear production—but without a placebo control, we can't be certain the drops caused the improvement. The glaucoma study (60 patients) was properly controlled but didn't reach its main goal, though it showed promising trends. The macular degeneration data is just a few case reports—interesting but very preliminary.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"NGF eye drops cure dry eye disease"” | Phase IIa open-label trial (N=40) showed significant improvement in symptoms and signs over 28 days. No placebo-controlled trial exists. | Mixed Evidence |
| “"NGF protects the optic nerve in glaucoma"” | Phase 1b RCT (N=60) showed trends but no statistical significance on primary endpoint. Animal models strongly support the mechanism. | Mixed Evidence |
| “"NGF eye drops can treat macular degeneration"” | Case reports only (PMID 20061666). No clinical trial data. Electrophysiological improvement noted but N is very small. | Preclinical Only |
| “"NGF restores tear production"” | Schirmer test scores improved in the Phase IIa dry eye trial. Mechanism is biologically plausible (neurotrophic loop restoration). | Mixed Evidence |
| “"Topical NGF reaches the retina"” | Case report AMD data implies posterior segment effects. No pharmacokinetic study has measured retinal NGF concentrations after topical dosing. | Theoretical |
| “"NGF is safer than anti-VEGF injections for retinal diseases"” | No head-to-head comparison exists. NGF eye drops have a favorable safety profile (eye pain, tearing) but treat different conditions than anti-VEGF agents. | Unsupported |
| “"NGF reverses corneal nerve damage in dry eye"” | Phase IIa data showed improved corneal staining (indirect evidence of nerve recovery). No confocal microscopy nerve density data from the dry eye study. | Mixed Evidence |
| “"NGF can replace current glaucoma medications"” | NGF is neuroprotective, not pressure-lowering. Current glaucoma drugs lower IOP. NGF would be adjunctive, not a replacement. | Unsupported |
| “"Both dose levels of NGF work equally well"” | In the Phase IIa dry eye trial, both 20 mcg/mL and 4 mcg/mL showed improvement. Without placebo comparison, dose-response cannot be established. | Mixed Evidence |
| “"NGF is the same molecule as cenegermin"” | Correct. rhNGF used in these studies is the same recombinant human NGF as cenegermin (Oxervate). Same molecule, different indications under investigation. | Supported |
| “"NGF will be approved for dry eye soon"” | No Phase III trial is registered or underway for dry eye as of 2025. Regulatory approval requires Phase III data. Timeline is unknown. | Unsupported |
| “"NGF has no serious side effects"” | In studies to date, NGF eye drops caused only mild effects (eye pain, tearing, foreign body sensation). No serious ocular adverse events reported. But total patient exposure is small (~100 patients across all non-NK studies). | Mixed Evidence |
The Human Evidence Landscape
The human evidence for NGF in non-NK ocular conditions is thin but real—three small studies spanning three different indications, all from the same research ecosystem.
Dry Eye Phase IIa (Sacchetti et al., 2019)
Design: Open-label Phase IIa. N: 40 patients with moderate-to-severe dry eye disease. Intervention: rhNGF eye drops (20 mcg/mL and 4 mcg/mL) for 28 days. Primary findings: Significant improvement in OSDI symptom scores, corneal fluorescein staining, and Schirmer test (tear volume). Limitations: No placebo arm. No masking. 28-day duration—dry eye is chronic. No long-term follow-up. PMID: 30944103.
Glaucoma Phase 1b RCT (2021)
Design: Randomized, controlled Phase 1b. N: 60 glaucoma patients on standard IOP-lowering therapy. Intervention: Short-course topical rhNGF vs. placebo. Primary findings: No statistically significant neuroenhancement on primary analysis. Trends in visual field sensitivity and RNFL thickness favored NGF. Safety acceptable. Limitations: Underpowered for efficacy—designed primarily for safety and dose-finding. Short treatment course for a chronic, slowly progressive disease. PMID: 34780798.
AMD Case Reports (Lambiase et al., 2009)
Design: Case report series. N: ~3 patients. Intervention: NGF eye drops. Primary findings: Improved visual acuity and electrophysiological measures (ERG, VEP). Limitations: Case reports—no control, no blinding, no statistical analysis. No subsequent confirmatory study. PMID: 20061666.
What's Missing
No Phase III trial exists for any non-NK indication. No long-term efficacy or safety data beyond 28 days. No dose-optimization study with placebo control. No confocal microscopy data confirming corneal nerve regeneration in dry eye (unlike the NK data). No pharmacokinetic study measuring retinal NGF levels after topical dosing. The human evidence landscape is a collection of encouraging signals, not a body of confirmatory proof.
PLAIN ENGLISH
About 100 total patients have received NGF eye drops for conditions other than the one it's approved for. The dry eye study was the most convincing (real improvements) but had no placebo comparison. The glaucoma study was well-designed but too small to prove anything definitively. The macular degeneration data is just a few individual patient reports. Nobody has run the large, rigorous trials needed to know whether NGF truly works for these conditions.
Safety, Risks, and Limitations
Known Adverse Effects
The safety profile of topical NGF is consistent across all ocular studies and mirrors the cenegermin (Oxervate) experience: - Eye pain — the most common adverse event, typically mild and transient - Increased lacrimation — paradoxically, in dry eye patients, this may be a therapeutic effect rather than an adverse event - Foreign body sensation — common with any eye drop but reported at slightly higher rates with NGF - Eye pruritus (itching) — mild, self-resolving
No serious ocular adverse events have been reported in any NGF eye drop study. No vision-threatening complications. No significant systemic absorption at topical doses.
Limitations and Concerns
Small total exposure. Approximately 100 patients have received NGF eye drops for non-NK indications. This is insufficient to detect rare adverse events.
p75NTR signaling uncertainty. In pathological conditions—particularly advanced glaucoma where pro-NGF accumulates—the balance between TrkA (survival) and p75NTR (death) signaling could theoretically shift in an unfavorable direction. No clinical evidence of this has been observed, but the theoretical concern exists.
Posterior segment penetration unknown. If NGF cannot reliably reach the retina after topical administration, the AMD and glaucoma applications face a fundamental delivery challenge. No pharmacokinetic study has confirmed retinal bioavailability of topically applied NGF.
Cost considerations. Oxervate costs approximately $9,000 per treatment course for NK. If NGF were approved for dry eye (a chronic condition requiring ongoing treatment), cost would be a major barrier unless pricing structures changed dramatically.
CRITICAL DISCLAIMER
NGF eye drops for non-NK indications are investigational. They are not available outside clinical trials for dry eye, glaucoma, or AMD. Do not use Oxervate (approved for NK) off-label for these conditions without specialist guidance—the dosing, duration, and clinical context are different.
Legal and Regulatory Status
NGF (as cenegermin/Oxervate) is FDA-approved for neurotrophic keratitis only. For dry eye disease, glaucoma, and AMD, NGF remains investigational with no active Phase III programs as of 2025. The EMA approved cenegermin for NK in 2017 (Oxervate). No regulatory pathway for expanded indications has been publicly disclosed by Dompé. Off-label use of Oxervate for dry eye or glaucoma is technically possible but not supported by Phase III evidence and would be at the prescribing physician's discretion. WADA does not prohibit NGF.
Research Protocols and Formulation Considerations
Clinical studies used recombinant human NGF (rhNGF) at 20 mcg/mL as topical ophthalmic drops—the same formulation and concentration as cenegermin (Oxervate). The dry eye Phase IIa also tested 4 mcg/mL. Drops were administered multiple times daily. NGF is a protein requiring cold-chain storage. The Oxervate formulation requires frozen storage until use—a significant practical limitation for any chronic-use indication like dry eye. Dompé would likely need to develop a more stable formulation for expanded indications requiring long-term daily dosing. No compounding or self-experimentation community exists for NGF eye drops—this is a pharmaceutical-grade recombinant protein, not a peptide available through research chemical vendors.
Dosing in Published Research
| Study | Concentration | Frequency | Duration | Route |
|---|---|---|---|---|
| Dry eye Phase IIa (PMID 30944103) | 20 mcg/mL and 4 mcg/mL | Multiple daily drops | 28 days | Topical ophthalmic |
| Glaucoma Phase 1b (PMID 34780798) | rhNGF (dose not fully published) | Short course | Per protocol | Topical ophthalmic |
| AMD case reports (PMID 20061666) | NGF eye drops | Per protocol | Variable | Topical ophthalmic |
Note: These are investigational protocols. No established clinical dosing exists for dry eye, glaucoma, or AMD. The approved Oxervate dosing for NK (one drop in the affected eye six times daily for eight weeks) may not be appropriate for other indications with different pathophysiology and treatment durations.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into NGF (Ocular Applications Beyond NK) combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining NGF (Ocular Applications Beyond NK) with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Evidence Tier | Verdict | Primary Mechanism | Target Tissue | Primary Indication | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|---|
| Cenegermin | Recombinant human NGF (118 aa homodimer, 0.002% eye drops) | Tier 1 — Approved Drug | Strong Foundation | TrkA/p75NTR → corneal epithelial survival + nerve regeneration | Cornea | Neurotrophic keratitis | Phase III RCTs (N=48 US + N=156 EU); 69.6% vs 29.2% healing | Approved August 2018 (Oxervate) | Not prohibited | 6 drops/day × 8 weeks; frozen storage; high cost; NK indication only |
| Anti-VEGF Peptides | Aptamer (pegaptanib) + antibody fragments (ranibizumab/brolucizumab) + fusion protein (aflibercept) | Tier 1 — Approved Drug | Strong Foundation | VEGF-A neutralization → anti-angiogenesis + anti-permeability | Retina | nAMD; DME; RVO | VISION (N=1,186); MARINA (N=716); VIEW (N=2,419) | Multiple agents approved (2004–2019+) | Not prohibited | Repeated intravitreal injections; endophthalmitis risk; treatment burden |
| RGN-259 | Thymosin β4 (43 aa) 0.1% ophthalmic solution | Tier 2 — Clinical Trials | Reasonable Bet | Actin sequestration → epithelial migration + anti-inflammatory | Cornea | Neurotrophic keratopathy; dry eye | Phase III NK (N=18; 60% vs 12.5%); Phase II dry eye (N=120) | Not approved (Phase III complete) | Not prohibited | Small Phase III N; competing with approved cenegermin; regulatory path pending |
| NGF (Ocular) | Recombinant human NGF (same as cenegermin, broader indications) | Tier 3 — Limited Human Data | Reasonable Bet | TrkA → neuroprotection (RGC) + tear film + epithelial trophism | Cornea; retina | Dry eye; glaucoma neuroprotection; AMD | Phase IIa dry eye (N=40); Phase 1b glaucoma (N=60) | Approved for NK only (Oxervate); not approved for dry eye/glaucoma | Not prohibited | No Phase III for non-NK indications; glaucoma Phase 1b showed trends only |
| SP/IGF-1 Ocular | Tetrapeptide combination (FGLM-NH₂ + SSSR eye drops) | Tier 3 — Limited Human Data | Reasonable Bet | SP/NK-1R priming + IGF-1R adhesion → synergistic epithelial migration | Cornea | Neurotrophic keratopathy (persistent epithelial defects) | Open-label (N=9; 89% healing) | Not approved; no commercial development | Not prohibited | Single research group (Japan); open-label only; no commercial developer |
| Octreotide (Intravitreal) | Cyclic octapeptide SSA (systemic or experimental intravitreal) | Tier 3 — Limited Human Data | Eyes Open | SSTR2/5 → anti-angiogenic + neuroprotective in retina | Retina | Diabetic retinopathy (proliferative) | Small randomized study (N=46; reduced vitreous hemorrhage) | Not approved for retinal use | Not prohibited | Eclipsed by anti-VEGF therapy; no active development program |
| PL-8177 (Ocular) | Selective MC1R agonist (theoretical ocular formulation) | Tier 4 — Preclinical Only | Eyes Open | MC1R → NF-κB suppression → ocular anti-inflammatory | Uvea; conjunctiva | Uveitis; dry eye inflammation (theoretical) | None for ocular use | Not approved; no ocular development | Not prohibited | Entirely theoretical; no ocular formulation or clinical data; IBD is active program |
Frequently Asked Questions
Is NGF for dry eye the same molecule as Oxervate?
Yes. The NGF tested in dry eye studies is the same recombinant human nerve growth factor used in Oxervate (cenegermin). The molecule is identical—only the target condition and treatment context differ.
Can I get Oxervate prescribed for dry eye?
Oxervate is FDA-approved only for neurotrophic keratitis. A physician could theoretically prescribe it off-label for dry eye, but no Phase III evidence supports this use, and the cost (~$9,000 per course) would be prohibitive for a chronic condition.
How is NGF for the eye different from oral or injectable NGF?
Topical ophthalmic NGF delivers the protein directly to the ocular surface, minimizing systemic exposure. The eye has unique access routes—corneal absorption, transconjunctival penetration, and potentially retrograde neural transport—that oral or injectable routes cannot replicate for ocular conditions.
When will NGF be approved for dry eye?
No Phase III trial is currently registered for NGF in dry eye disease as of 2025. Regulatory approval requires Phase III data, so even optimistically, approval is years away if a trial were initiated tomorrow.
Does NGF lower eye pressure in glaucoma?
No. NGF is neuroprotective—it protects retinal ganglion cells from dying—but does not lower intraocular pressure. It would supplement, not replace, standard pressure-lowering glaucoma medications.
How can eye drops reach the retina for glaucoma or AMD?
The exact mechanism is not fully established. Proposed routes include retrograde axonal transport along corneal nerves, transconjunctival absorption into the scleral circulation, and lateral diffusion through ocular tissues. The case report evidence showing retinal effects after topical dosing suggests some posterior segment delivery occurs, but no pharmacokinetic study has confirmed retinal drug levels.
Is there a generic version of NGF eye drops?
No. NGF is a complex recombinant protein that cannot be produced as a simple generic. Any future competitors would need to develop biosimilars, which require their own clinical testing programs.
What side effects have been seen in dry eye and glaucoma studies?
Mild and transient effects: eye pain, increased tearing, foreign body sensation, and itching. No serious ocular adverse events have been reported. However, total patient exposure is small (~100 patients across all non-NK studies).
How does NGF compare to cyclosporine or lifitegrast for dry eye?
NGF targets a different mechanism—nerve regeneration and neurotrophic loop restoration—rather than the anti-inflammatory approach of cyclosporine (Restasis) or lifitegrast (Xiidra). They could potentially be complementary rather than competitive, but no head-to-head comparison exists.
Could NGF be combined with anti-VEGF injections for AMD?
Theoretically, NGF (neuroprotective) and anti-VEGF agents (anti-angiogenic) target different aspects of AMD pathology and could be complementary. No study has tested this combination. The practical advantage would be that NGF eye drops could provide ongoing neuroprotection between periodic anti-VEGF injections.
Why hasn't Dompé started Phase III trials for dry eye?
Dompé has not publicly disclosed its development timeline for non-NK indications. Possible reasons include strategic prioritization of the NK market, the need for a more stable formulation for chronic daily use, and the high cost and complexity of Phase III dry eye trials (large N, long duration, subjective endpoints).
Is the p75NTR receptor a safety concern for NGF therapy?
In theory, under certain pathological conditions, NGF signaling through p75NTR could promote cell death rather than survival. This is particularly relevant in advanced glaucoma where pro-NGF (the unprocessed precursor) may accumulate. No clinical evidence of p75NTR-mediated harm has been observed with topical NGF, but it remains an area of active research and a theoretical concern for long-term use.
Summary of Key Findings
1. Nerve growth factor (NGF) is already proven in the eye. Cenegermin's FDA approval for neurotrophic keratitis validates that topical NGF can regenerate ocular nerves and heal the corneal surface. The biological platform is real.
2. The dry eye signal is the strongest non-NK evidence. A Phase IIa trial in 40 patients showed meaningful improvement in both symptoms and objective signs. But without placebo control, the signal requires Phase III confirmation.
3. Glaucoma neuroprotection remains unproven. A Phase 1b RCT in 60 patients showed promising trends but failed to reach statistical significance on its primary endpoint. The concept—protecting retinal ganglion cells independent of pressure control—is scientifically important but clinically premature.
4. AMD data is case-report-level only. A handful of patients showed improved retinal function with NGF drops. This is hypothesis-generating, not evidence of efficacy.
5. No Phase III trial exists for any non-NK indication. The entire beyond-NK platform sits at Phase IIa or earlier. Timelines for further development are unknown.
6. The safety profile is reassuring but based on small numbers. Approximately 100 patients have received NGF drops for non-NK conditions, with only mild adverse events reported.
PLAIN ENGLISH
NGF eye drops definitely work for one rare eye disease (neurotrophic keratitis—that's proven). The early evidence suggests they might also help with dry eye, glaucoma, and macular degeneration, but the studies so far are too small and too early to prove it. The biggest single gap is that no large, rigorous trial has been run for any of these newer uses.
Verdict Recapitulation
The biology is validated—cenegermin's approval proves NGF works in the eye. But approval for one condition does not guarantee efficacy in others. The Phase IIa dry eye data is encouraging, the Phase 1b glaucoma data is inconclusive, and the AMD data is anecdotal. Reasonable Bet because the mechanistic foundation is as strong as it gets in ophthalmology—a Nobel Prize-winning molecule with an FDA-approved ocular formulation—but the clinical evidence for expanded indications has not yet caught up with the biology.
For readers considering NGF (Ocular Applications Beyond NK), the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source NGF (Ocular Applications Beyond NK)
Further Reading and Resources
If you want to go deeper on NGF (Ocular Applications Beyond NK), the evidence landscape for vision & ocular peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Vision & Ocular Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: NGF (Ocular Applications Beyond NK) — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sacchetti, M. et al. (2019). "Topical recombinant nerve growth factor for dry eye disease: a Phase IIa open-label study." Investigative Ophthalmology & Visual Science. PMID 30944103
- Phase 1b Glaucoma RCT (2021). "Topical recombinant human nerve growth factor for glaucoma neuroprotection: a Phase 1b randomized controlled trial." PMID 34780798
- Lambiase, A. et al. (2009). "Nerve growth factor eye drops improve visual acuity and electrofunctional activity in age-related macular degeneration: a case report." Annali dell'Istituto Superiore di Sanità. PMID 20061666
- Lambiase, A. et al. (2009). "Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma." Graefe's Archive for Clinical and Experimental Ophthalmology. PMID 19805021
- Bonini, S. et al. (2018). "Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis." Ophthalmology, 125(9), 1332–1343. PMID 29653860 [Reference trial establishing NGF ocular biology—cenegermin Phase II]
DISCLAIMER
NGF (Ocular Applications Beyond NK) is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 11, 2026. Next scheduled review: October 08, 2026.